72224-27-2

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneacetic acid, 4-(2-oxiranylmethoxy)-, methyl ester is used as a reactant for the preparation of non-peptidic propargylamines, which are compounds of interest in the development of inhibitors targeting Lysine Specific Demethylase 1 (LSD1). LSD1 is an enzyme involved in the regulation of gene expression, and its inhibition has potential therapeutic applications in the treatment of various diseases, including cancer and neurological disorders.

Upstream product

• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 106-89-8 epichlorohydrin 
• 156-38-7 4-hydroxyphenylacetate 

Downstream Products

• 116662-70-5 (S)-1-[4-(methoxycarbonylmethyl)-phenoxy]-2,3-epoxypropane 
• 83281-59-8 methyl 4-[2-Hydroxy-3-(isopropylamino)propoxy]phenylacetate hydrochloride 
• 29121-23-1 methyl (±)-2-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)acetate 
• 1453205-24-7 methyl 2-[4-[2-hydroxy-3-[methyl(prop-2-nyl)amino]propoxy]phenyl]acetate 
• 1453205-25-8 methyl 2-[4-[2-hydroxy-3-(prop-2-ynylamino)propoxy]phenyl]acetate 

Relevant academic research and scientific papers

Novel naftopidil derivatives containing methyl phenylacetate and their blocking effects on α1D/1A-adrenoreceptor subtypes

α1-Adrenoceptor (α1-AR) antagonists are considered to be the most effective monotherapy agents for lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). In this study, we synthesized compounds 2–17, which are novel piperazine derivatives that contain methyl phenylacetate. We then evaluated the vasodilatory activities of these compounds. Among them, we found that compounds 2, 7, 12, which contain 2-OCH3, 2-CH3 or 2, 5-CH3, respectively, exhibited potent α1-blocking activity similar to protype drug naftopidil (1). The antagonistic effects of 2, 7, and 12 on the (?)-noradrenaline-induced contractile response of isolated rat prostatic vas deferens (α1A), spleen (α1B) and thoracic aorta (α1D) were further characterized to assess the sub receptor selectivity. Compared with naftopidil (1) and terazosin, compound 12 showed the most desirable α1D/1A subtype selectivity, especially improved α1A subtype selectivity, and the ratios pA2 (α1D)/pA2 (α1B) and pA2 (α1A)/pA2 (α1B) were 17.0- and 19.5-fold, respectively, indicating less cardiovascular side effects when used to treat LUTS/BPH. Finally, we investigated the chiral pharmacology of 12. We found, however, that the activity of enantiomers (R)-12 and (S)-12 are not significantly different from that of rac-12.

Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity

Lysine demethylases play an important role in epigenetic regulation and thus in the development of diseases like cancer or neurodegenerative disorders. As the lysine specific demethylase 1 (LSD1/KDM1) has been strongly connected to androgen and estrogen dependent gene expression, it serves as a promising target for the therapy of hormone dependent cancer. Here, we report on the discovery of new small molecule inhibitors of LSD1 containing a propargylamine warhead, starting out from lysine containing substrate analogues. On the basis of these substrate mimicking inhibitors, we were able to increase potency by a combination of similarity-based virtual screening and subsequent synthetic optimization resulting in more druglike LSD1 inhibitors that led to histone hypermethylation in breast cancer cells.

Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors

Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.

METHOD FOR TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS

A method for the treatment of prophylaxis of cardiac disorders in a mammal, comprising administering to such mammal a short-acting β-blocking compound of the formula: STR1 wherein R may be lower alkyl, aryl, or aralkyl; n may be an integer from 0 to about 10; x may be an integer from 1 to 3; Ar may be substituted or unsubstituted aromatic; R. sub.1 may be lower alkyl, or aralkyl; and pharmaceutically accepted salts thereof. Novel compounds possessing short-acting β-adrenergic blocking activity are also disclosed.

Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 2. (Aryloxy)propanolamines Containing Esters on the Aryl Function

Several short-acting β-adrenergic receptor blocking agents have been prepared by incorporating ester functions into the aryl portion of certain (aryloxy)propanolamine systems.In particular, methyl 3-phenyl>propionate hydrochloride (ASL-8052) was found to be a moderately potent, cardioselective compound with a short duration of action when determined in in vivo canine models.